MindWalk Holdings Corp HYFT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
-
MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director
-
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
-
MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027
-
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
-
MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion
-
MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2027 on September 14, 2026
Trading Information
- Previous Close Price
- $1.34
- Day Range
- $1.33–1.51
- 52-Week Range
- $0.99–2.99
- Bid/Ask
- $1.44 / $1.52
- Shares Outstanding
- 47.11M
- Market Cap
- $70.20M
- Volume/Avg
- 570,239 / 198,740
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 77
- Website
- https://www.mindwalkai.com
Valuation
|
Metric
|
HYFT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.77 |
Price/Sales | 5.33 |
Price/Cash Flow | — |
Price/Earnings
HYFT
Financial Strength
|
Metric
|
HYFT
|
|---|---|
Quick Ratio | 1.63 |
Current Ratio | 1.84 |
Interest Coverage | — |
Quick Ratio
HYFT
Profitability
|
Metric
|
HYFT
|
|---|---|
Return on Assets (Normalized) | −56.45% |
Return on Equity (Normalized) | −100.81% |
Return on Invested Capital (Normalized) | −81.30% |
Return on Assets
HYFT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G$>HDP | LOCK|!sXF | $128B | |||
| Moderna Inc
MRNA
| LOCK|lBXPykk | LOCK|l%? | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|D<!^pt | LOCK|?!^? | $75B | |||
| argenx SE ADR
ARGX
| LOCK|bRF^>& | LOCK|mF | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#!Zbf@d | LOCK|kj | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|y>$w<@! | LOCK|M#@<J | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^FW>JQkn | LOCK|QlKXk | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|lCT>>sk | LOCK|@ls | $25B | |||
| Incyte Corp
INCY
| LOCK|DTq%h> | LOCK|&^C | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|M^s!K$ | LOCK|bJl | $15B |
United States